Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1%

Marco Coassin, Michele De Maria, Valentina Mastrofilippo, Luca Braglia, Luca Cimino, Antonio Sartori, Luigi Fontana

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the efficacy of bromfenac 0.09% and dexamethasone 0.1% in the treatment of anterior chamber inflammation after uncomplicated cataract surgery. Methods: Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to receive dexamethasone ophthalmic suspension 0.1% or bromfenac ophthalmic solution 0.09% for 2 weeks. All patients were examined on the day before surgery and postoperatively at day 1, 3, 7, 9, 11, 14 and 30. Laser flare photometry was used to quantify anterior chamber inflammation and optical coherence tomography to measure macular thickness. Results: Bromfenac was as effective as dexamethasone in reducing inflammation in the anterior chamber of the eye. Laser flare increased the day after surgery and progressively decreased after starting the treatment with no statistically significant difference between dexamethasone and bromfenac at all time points. Visual acuity improved steadily after surgery in both groups. Mean macular thickness was similar in both the dexamethasone and bromfenac arms at 1 month. Conclusions: Short-term therapy with topical bromfenac alone is as effective as dexamethasone in low-risk cataract surgery patients. Trial Registration: ClinicalTrials.gov # NCT03317847; EudraCT # 2016-004358-14. Funding: Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy.

Original languageEnglish
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Anterior Chamber
Cataract
Dexamethasone
Randomized Controlled Trials
Inflammation
Ambulatory Surgical Procedures
Lasers
Photometry
Phacoemulsification
Ophthalmic Solutions
Optical Coherence Tomography
Italy
Visual Acuity
bromfenac
Comorbidity
Suspensions
Arm
Therapeutics

Keywords

  • Cataract surgery
  • Laser flare photometry
  • Non-steroidal anti-inflammatory drugs
  • Ophthalmology

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anterior Chamber Inflammation After Cataract Surgery : A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1%. / Coassin, Marco; De Maria, Michele; Mastrofilippo, Valentina; Braglia, Luca; Cimino, Luca; Sartori, Antonio; Fontana, Luigi.

In: Advances in Therapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{c76e2708cc4f4043aa3eb2ece49d1458,
title = "Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09{\%} to Dexamethasone 0.1{\%}",
abstract = "Purpose: To compare the efficacy of bromfenac 0.09{\%} and dexamethasone 0.1{\%} in the treatment of anterior chamber inflammation after uncomplicated cataract surgery. Methods: Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to receive dexamethasone ophthalmic suspension 0.1{\%} or bromfenac ophthalmic solution 0.09{\%} for 2 weeks. All patients were examined on the day before surgery and postoperatively at day 1, 3, 7, 9, 11, 14 and 30. Laser flare photometry was used to quantify anterior chamber inflammation and optical coherence tomography to measure macular thickness. Results: Bromfenac was as effective as dexamethasone in reducing inflammation in the anterior chamber of the eye. Laser flare increased the day after surgery and progressively decreased after starting the treatment with no statistically significant difference between dexamethasone and bromfenac at all time points. Visual acuity improved steadily after surgery in both groups. Mean macular thickness was similar in both the dexamethasone and bromfenac arms at 1 month. Conclusions: Short-term therapy with topical bromfenac alone is as effective as dexamethasone in low-risk cataract surgery patients. Trial Registration: ClinicalTrials.gov # NCT03317847; EudraCT # 2016-004358-14. Funding: Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy.",
keywords = "Cataract surgery, Laser flare photometry, Non-steroidal anti-inflammatory drugs, Ophthalmology",
author = "Marco Coassin and {De Maria}, Michele and Valentina Mastrofilippo and Luca Braglia and Luca Cimino and Antonio Sartori and Luigi Fontana",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12325-019-01076-4",
language = "English",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",

}

TY - JOUR

T1 - Anterior Chamber Inflammation After Cataract Surgery

T2 - A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1%

AU - Coassin, Marco

AU - De Maria, Michele

AU - Mastrofilippo, Valentina

AU - Braglia, Luca

AU - Cimino, Luca

AU - Sartori, Antonio

AU - Fontana, Luigi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To compare the efficacy of bromfenac 0.09% and dexamethasone 0.1% in the treatment of anterior chamber inflammation after uncomplicated cataract surgery. Methods: Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to receive dexamethasone ophthalmic suspension 0.1% or bromfenac ophthalmic solution 0.09% for 2 weeks. All patients were examined on the day before surgery and postoperatively at day 1, 3, 7, 9, 11, 14 and 30. Laser flare photometry was used to quantify anterior chamber inflammation and optical coherence tomography to measure macular thickness. Results: Bromfenac was as effective as dexamethasone in reducing inflammation in the anterior chamber of the eye. Laser flare increased the day after surgery and progressively decreased after starting the treatment with no statistically significant difference between dexamethasone and bromfenac at all time points. Visual acuity improved steadily after surgery in both groups. Mean macular thickness was similar in both the dexamethasone and bromfenac arms at 1 month. Conclusions: Short-term therapy with topical bromfenac alone is as effective as dexamethasone in low-risk cataract surgery patients. Trial Registration: ClinicalTrials.gov # NCT03317847; EudraCT # 2016-004358-14. Funding: Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy.

AB - Purpose: To compare the efficacy of bromfenac 0.09% and dexamethasone 0.1% in the treatment of anterior chamber inflammation after uncomplicated cataract surgery. Methods: Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to receive dexamethasone ophthalmic suspension 0.1% or bromfenac ophthalmic solution 0.09% for 2 weeks. All patients were examined on the day before surgery and postoperatively at day 1, 3, 7, 9, 11, 14 and 30. Laser flare photometry was used to quantify anterior chamber inflammation and optical coherence tomography to measure macular thickness. Results: Bromfenac was as effective as dexamethasone in reducing inflammation in the anterior chamber of the eye. Laser flare increased the day after surgery and progressively decreased after starting the treatment with no statistically significant difference between dexamethasone and bromfenac at all time points. Visual acuity improved steadily after surgery in both groups. Mean macular thickness was similar in both the dexamethasone and bromfenac arms at 1 month. Conclusions: Short-term therapy with topical bromfenac alone is as effective as dexamethasone in low-risk cataract surgery patients. Trial Registration: ClinicalTrials.gov # NCT03317847; EudraCT # 2016-004358-14. Funding: Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy.

KW - Cataract surgery

KW - Laser flare photometry

KW - Non-steroidal anti-inflammatory drugs

KW - Ophthalmology

UR - http://www.scopus.com/inward/record.url?scp=85072205807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072205807&partnerID=8YFLogxK

U2 - 10.1007/s12325-019-01076-4

DO - 10.1007/s12325-019-01076-4

M3 - Article

C2 - 31482510

AN - SCOPUS:85072205807

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -